|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||17.48 - 18.06|
|52 Week Range||13.41 - 18.06|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||30.31|
|Forward Dividend & Yield||0.39 (2.24%)|
|Ex-Dividend Date||Mar 29, 2021|
|1y Target Est||N/A|
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the presentation of new data in acute myeloid leukemia (AML) at the European Hematology Association (EHA) virtual congress, taking place June 9-17.
Japanese shares closed lower on Monday, as investors locked in gains after a recent rally, although the losses were limited by a positive finish from local drugmakers. The Nikkei had jumped 2.1% on Friday to close at the 29,000-level for the first time since May 10, while Wall Street finished with marginal gains.
Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced updated results from two clinical trials examining PADCEV® (enfortumab vedotin-ejfv) alone (EV-201 Cohort 2) and PADCEV in combination with Merck’s (known as MSD outside the United States and Canada) KEYTRUDA® (pembrolizumab) (EV-103 Cohort A) in patients with locally advanced or metastatic urothelial cancer who are not able to receive cisplatin chemotherapy.